Ipriflavone prevents the bone mass reduction in premenopausal women treated with gonadotropin hormone-releasing hormone agonists

https://doi.org/10.1016/S0169-6009(08)80159-6Get rights and content

Abstract

In the present study we assessed the effects of ipriflavone in the prevention of increased bone turnover and the rapid bone loss that follows medical induced hypogonadism caused by the administration of a gonadotropin hormone-releasing hormone agonist (GnRH-A). In a double blind, placebo-controlled study, ipriflavone (600 mg/day, tdd (three divided doses)) or identical placebo tablets were given with 500 mg/day of calcium to patients treated with 3.75 mg leuproreline acetate every 30 days, for 6 months. In placebo-treated subjects (n = 39), urinary hydroxyproline excretion and plasma bone GLA protein levels showed a substantial (P < 0.01) increase, while spine bone density and total body bone density significantly (P < 0.01) decreased after 3 and 6 months of GnRH-A administration. Conversely, in ipriflavone treated group (n = 39), no significant difference in bone markers and bone density was evidenced. These data indicate that ipriflavone can restrain the bone remodeling processes and prevent the rapid bone loss that follows medical induced hypogonadism. Thus, ipriflavone administration can be of value in the prevention of osteopenia in women treated with GnRH-A.

References (31)

  • JB Jacobson

    Effects of nafarelin on bone density

    Am J Obstet Gynecol

    (1990)
  • HL Judd

    Gonadotropin releasing hormone agonists: strategies for managing the hypoestrogenic effects of therapy

    Am J Obstet Gynecol

    (1992)
  • I Yamazaki et al.

    Effect of ipriflavone on glucocorticoid-induced osteoporosis in rats

    Life Sci

    (1986)
  • JP Devoggelaer et al.

    LHRH Analogues and bone loss

    Lancet

    (1987)
  • WH Matta et al.

    Hypogonadism induced by luteinising hormone-releasing hormone agonist analogues: effects on bone density in premenopausal women

    Br Med J

    (1987)
  • WH Matta et al.

    Reversible trabecular bone density loss following induced hypoestrogenism with the GnRH analogue buserelin in premenopausal women

    Clin Endocrinol

    (1988)
  • JS Johansen et al.

    The effect of a gonado-tropin-releasing hormone agonist analog (nafarelin) on bone metabolism

    J Clin Endocrinol Metab

    (1988)
  • MY Dawood et al.

    Cortical and trabecular bone mineral content in women with endometriosis: effect of gonadotropin-releasing hormone agonist and danazol

    Fertil Steril

    (1989)
  • AR Schalli et al.

    Leuprolide acetate and bone mineral density measured by quantitative digitized radiography

    Fertil Steril

    (1993)
  • BJ Riis et al.

    Is it possible to prevent bone loss in young women treated with luteinizing hormone-releasing hormone agonists?

    J Clin Endocrinol Metab

    (1990)
  • ES Surrey et al.

    Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial

    J Clin Endocrinol Metab

    (1992)
  • CP West et al.

    Potential role for medroxyprogesterone acetate as an adjunct to goserelin (Zoladex) in the medical treatment of uterine fibroids

    Hum Reprod

    (1992)
  • AT Leather et al.

    The prevention of bone loss in young women treated with GnRH Analogues with “add-back” estrogen therapy

    Obstet Gynecol

    (1993)
  • A Suda

    Effect of parathyroid hormone on parietal bones of rats and effect of ipriflavone

    J Bone Min Metab

    (1987)
  • E Bonucci et al.

    Ipriflavone inhibits osteoclast differentiation in parathyroid transplanted parietal bone of rats

    Calcif Tissue Int

    (1992)
  • Cited by (38)

    • Use of alternative therapies in menopause

      2002, Best Practice and Research: Clinical Obstetrics and Gynaecology
    View all citing articles on Scopus
    View full text